Hypertension Diagnostics, Inc. Newsroom


	CVProfilor^® System Drew Sizeable Attention at American College of Cardiology Conference ST. PAUL, MN – April 16, 2002 – Hypertension Diagnostics, Inc. (NASDAQ SmallCap: HDII), announced today that more than 500 physicians and health care professionals received a personalized CVProfile™ Report during this year’s 51st Annual Scientific Session of the American College of Cardiology (ACC) meeting held in Atlanta, Georgia on March 17-19, 2002, courtesy of Novartis Pharmaceuticals Corporation, a division of Norvartis International AG, Basel, Switzerland, a major multi-national pharmaceutical firm.
	Greg H. Guettler, President of Hypertension Diagnostics said, “Due to the growing medical interest in arterial elasticity, the CVProfilor^® DO-2020 and methods with which to improve arterial elasticity, Novartis Pharmaceuticals retained HDI to provide CVProfile™ Reports to visitors in their booth at the American College of Cardiology meeting in Atlanta, Georgia. The result was that more than 500 individuals received a personalized CVProfile™ Report giving them new information on the health status of their blood vessels.” Current scientific studies indicate that some cardiovascular drugs improve arterial elasticity. Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for medical applications and clinical research. These systems are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world. In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries which is a unique feature of HDI’s technology. Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated. CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Investor Relations: Jens Dalsgaard and Tony Altavilla, Managing Directors Redwood Consultants, LLC Mill Valley, CA 94941 415-380-0500 Contact: Greg H. Guettler, President Return to the Main HDI Newsroom Back to Top

Copyright © 2009 Hypertension Diagnostics, Inc Last revised Wednesday February 11, 2009 HDI Legal Information